Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat in Pediatric Sickle Cell Disease Patients at Risk for Stroke
NCT05953584Phase 2Recruiting
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of etavopivat in sickle cell disease (SCD), sponsored by Forma Therapeutics, Inc.. Started Jun 2023; status: recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05953584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953584.